汇丰晋信科技先锋股票（540010）成立日期2011年7月27日，最新规模5.79亿。今年以来收益73.22%， 同类排名73/4206；近一年收益74.7%，同类排名66/4006；成立以来收益226.66%。 11月27日，太辰光涨6.91%，截至发稿，报106.90元/股，成交12.35亿元，换手率6.26%，总市值242.80 亿元。太辰光股价已经连续3天上涨，区间累计涨幅14.93%。 资料显示，深圳太辰光通信股份有限公司位于广东省深圳市坪山区坑梓街道秀新社区锦绣中路8号太辰 光通信科技园-101(1、2、3号楼)(一照多址企业)，成立日期2000年12月12日，上市日期2016年12月6 日，公司主营业务涉及光器件的研发、生产和销售。主营业务收入构成为：光器件产品98.02%，其他 1.81%，光传感产品0.17%。 从基金十大重仓股角度 数据显示，汇丰晋信基金旗下1只基金重仓太辰光。汇丰晋信科技先锋股票（540010）三季度增持7.22 万股，持有股数32.19万股，占基金净值比例为5.85%，位居第六大重仓股。根据测算，今日浮盈赚取约 222.43万元。连续3天上涨期间浮盈赚取418.15万元 ...

Core Viewpoint - Blue Sky Technology's stock price has shown fluctuations, with a year-to-date increase of 14.12% but a recent decline over the past five and twenty trading days [1][2]. Financial Performance - For the period from January to September 2025, Blue Sky Technology achieved operating revenue of 1.933 billion yuan, representing a year-on-year growth of 2.20% [2]. - The net profit attributable to shareholders for the same period was 652 million yuan, reflecting a year-on-year increase of 9.27% [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Blue Sky Technology was 17,200, a decrease of 9.48% from the previous period [2]. - The average circulating shares per person increased by 10.47% to 17,786 shares [2]. Dividend Distribution - Since its A-share listing, Blue Sky Technology has distributed a total of 1.227 billion yuan in dividends, with 958 million yuan distributed over the past three years [3]. Major Shareholders - The largest circulating shareholder is Hong Kong Central Clearing Limited, holding 64.7688 million shares, an increase of 14.7239 million shares from the previous period [3]. - Other notable shareholders include E Fund's Growth Mixed Fund and Ruifeng Growth Value Mixed Fund, with varying changes in their holdings [3].

Core Viewpoint - Huaxi Biological experienced a decline in stock price, with a year-to-date drop of 4.52% and a significant decrease in revenue and net profit for the first nine months of 2025 compared to the previous year [1][2]. Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company is located in Jinan, Shandong Province, and focuses on microbial fermentation and cross-linking technology platforms to develop bioactive materials for health [1]. - The company has a full industry chain business model that includes raw materials, medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing companies, medical institutions, and end-users [1]. Financial Performance - For the period from January to September 2025, Huaxi Biological reported operating revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2]. - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed over the past three years [3]. Shareholder Information - As of November 20, 2025, Huaxi Biological had 30,100 shareholders, a decrease of 0.62% from the previous period, with an average of 16,014 circulating shares per shareholder, which increased by 0.62% [2]. - Major shareholders include various ETFs, with significant reductions in holdings noted for several funds, indicating a potential shift in institutional investment [3].

Group 1 - The core viewpoint of the news is that Tonglian Precision has seen a significant increase in its stock price, rising 5.15% to 55.10 CNY per share, with a total market capitalization of 8.918 billion CNY and a cumulative increase of 9.62% over the past three days [1] - Tonglian Precision, established on June 12, 2016, and listed on December 27, 2021, specializes in the research, design, production, and sales of high-precision, high-density, and complex-shaped precision components [1] - The main business revenue composition of Tonglian Precision includes 66.47% from other metal craft products and plastic products, 30.78% from MIM products, 1.43% from molds and tools, and 1.32% from other sources [1] Group 2 - In terms of major shareholders, the Invesco Great Wall Fund has entered the top ten circulating shareholders of Tonglian Precision, holding 2.5323 million shares, which is 1.57% of the circulating shares [2] - The Invesco Great Wall Stable Return Mixed A Fund (001194) has achieved a year-to-date return of 98.76%, ranking 27th out of 8,134 in its category, and a one-year return of 108.55%, ranking 21st out of 8,056 [2] - The fund manager, Jiang Shan, has a tenure of 4 years and 107 days, with the fund's total asset size at 36.787 billion CNY and a best return of 166.86% during his tenure [2]

Core Viewpoint - Yunda Co., Ltd. has shown a significant increase in stock price and trading activity, indicating positive market sentiment despite a slight decline in net profit year-on-year [1][2]. Financial Performance - For the period from January to September 2025, Yunda Co., Ltd. achieved a revenue of 18.486 billion yuan, representing a year-on-year growth of 32.72% [2]. - The net profit attributable to shareholders was 251 million yuan, which reflects a decrease of 5.76% compared to the previous year [2]. Stock Market Activity - On November 26, Yunda's stock price rose by 2.05%, reaching 17.42 yuan per share, with a trading volume of 112 million yuan and a turnover rate of 0.93% [1]. - The stock has increased by 32.17% year-to-date, with a 3.81% rise over the last five trading days, a 3.60% decline over the last 20 days, and a 2.59% increase over the last 60 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 13.08% to 33,400, while the average number of circulating shares per person increased by 15.09% to 20,891 shares [2]. - The company has distributed a total of 281 million yuan in dividends since its A-share listing, with 153 million yuan distributed over the last three years [3]. Major Shareholders - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 9.0248 million shares, a decrease of 1.7986 million shares from the previous period [3]. - Other notable shareholders include Huaxia Fuxing Mixed A and Bosera Hengle Bond A, with stable or new positions in the company [3].

Core Viewpoint - Postal Savings Bank of China (PSBC) experienced a decline in stock price, with a drop of 2.04% on November 26, trading at 5.76 CNY per share, and a total market capitalization of 691.75 billion CNY [1] Financial Performance - PSBC's stock price has increased by 6.31% year-to-date, with a slight rise of 0.52% over the last five trading days, but has seen a decline of 3.03% over the last 20 days and 8.13% over the last 60 days [2] - For the period from January to September 2025, PSBC reported a net profit of 76.56 billion CNY, reflecting a year-on-year growth of 0.98% [3] Business Operations - PSBC's main business segments include personal banking (65.15% of revenue), corporate banking (22.71%), and funding operations (12.10%) [2] - The bank provides a variety of financial services, including personal loans, corporate loans, and asset management [2] Shareholder Information - As of September 30, 2025, PSBC had 142,600 shareholders, a decrease of 13.09% from the previous period, with an average of 478,570 circulating shares per shareholder, an increase of 15.29% [3] - The bank has distributed a total of 137.80 billion CNY in dividends since its A-share listing, with 77.40 billion CNY distributed over the last three years [4] Institutional Holdings - As of September 30, 2025, major institutional shareholders include Hong Kong Central Clearing Limited and various ETFs, with notable reductions in their holdings compared to the previous period [4]

Group 1 - The core viewpoint of the news is that Taotao Automotive has seen a significant increase in its stock price, rising by 5.16% to 206.54 CNY per share, with a total market capitalization of 22.523 billion CNY [1] - Taotao Automotive, established on September 24, 2015, focuses on the research, production, and sales of electric vehicles and related accessories, with its main revenue sources being smart electric low-speed vehicles (67.23%), special vehicles (28.59%), and others (4.17%) [1] Group 2 - According to data, Huaxia Fund holds a significant position in Taotao Automotive, with its Huaxia Core Value Mixed A Fund (010692) being the second-largest holding, having reduced its shares by 1,600 to hold 30,200 shares, which represents 3.62% of the fund's net value [2] - The Huaxia Core Value Mixed A Fund has a total scale of 139 million CNY and has achieved a year-to-date return of 14.4%, ranking 4715 out of 8134 in its category [2]

Group 1 - The core point of the article highlights the recent performance of XinNuoWei, which saw a 5.2% increase in stock price, reaching 33.39 CNY per share, with a total market capitalization of 46.899 billion CNY [1] - XinNuoWei's main business involves the research, production, and sales of functional foods, with revenue composition being 88.93% from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1] Group 2 - From the perspective of major fund holdings, data shows that Nuoan Fund has a significant position in XinNuoWei, with its Nuoan Selected Value Mixed A Fund increasing its holdings by 470,600 shares in the third quarter, now holding a total of 954,300 shares, which constitutes 4.9% of the fund's net value [2] - The Nuoan Selected Value Mixed A Fund has achieved a year-to-date return of 73.05%, ranking 163 out of 8,134 in its category, and a one-year return of 57.82%, ranking 429 out of 8,056 [2] - The fund manager, Tang Chen, has been in charge for 2 years and 343 days, with the fund's total asset size at 1.317 billion CNY, achieving a best return of 76.25% during his tenure [2]

Core Viewpoint - The stock of Kexing Pharmaceutical has shown significant fluctuations, with a year-to-date increase of 57.84% and a recent decline over the past 20 and 60 days, indicating volatility in its market performance [1]. Financial Performance - For the period from January to September 2025, Kexing Pharmaceutical achieved a revenue of 1.148 billion yuan, representing a year-on-year growth of 10.54% [2]. - The net profit attributable to shareholders for the same period was 111 million yuan, reflecting a substantial year-on-year increase of 547.70% [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 25.03% to 11,800, while the average circulating shares per person decreased by 19.37% to 17,102 shares [2]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) six times this year, with the most recent appearance on July 3 [1]. Dividend Distribution - Since its A-share listing, Kexing Pharmaceutical has distributed a total of 51.5446 million yuan in dividends, with 15.7785 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, notable changes in institutional holdings include a decrease in shares held by the second-largest shareholder, E Fund Medical Care Industry Mixed A, by 1.6069 million shares, while the fifth-largest shareholder, Fortune Tianhui Growth Mixed A/B, increased its holdings by 10,000 shares [3].

11月26日，奥浦迈盘中上涨2.03%，截至09:49，报56.68元/股，成交354.27万元，换手率0.06%，总市值 64.51亿元。 奥浦迈今年以来股价涨57.23%，近5个交易日跌1.72%，近20日跌8.74%，近60日涨0.91%。 资料显示，上海奥浦迈生物科技股份有限公司位于上海市浦东新区紫萍路908弄28号楼，成立日期2013 年11月27日，上市日期2022年9月2日，公司主营业务涉及从事细胞培养产品与服务。主营业务收入构成 为：产品87.34%，服务12.53%，其他0.13%。 机构持仓方面，截止2025年9月30日，奥浦迈十大流通股东中，中欧医疗健康混合A（003095）位居第 六大流通股东，持股400.86万股，相比上期增加252.62万股。工银前沿医疗股票A（001717）位居第七 大流通股东，持股330.01万股，相比上期增加40.00万股。中欧医疗创新股票A（006228）位居第九大流 通股东，持股265.16万股，为新进股东。招商医药健康产业股票（000960）退出十大流通股东之列。 责任编辑：小浪快报 奥浦迈所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包 ...